The user is experiencing hair regrowth using finasteride, minoxidil, and KX-826. They regret not starting treatment earlier but are now seeing progress.
The discussion is about using ASCEplus HRLB exosomes for hair loss treatment, which combines 10 billion exosomes with growth factors, nutrients, biotin, and copper tripeptide. The treatment is expensive and typically administered via scalp injections, but in Europe, it's done with microneedling.
A 25-year-old male experiencing hair loss suspects stress-related alopecia and is hesitant to use Minoxidil due to potential side effects. Another user suggests it might be androgenic alopecia and recommends starting finasteride.
The user is generally happy with their hair transplant results but has concerns about graft density and placement, particularly on the left temple and hairline. They are using finasteride and minoxidil inconsistently, plan to add Priorin, and are considering microneedling and PRP sessions for future care.
A user shared impressive hair regrowth results after 4 months using topical minoxidil, oral finasteride, and 3 PRP sessions. They plan to continue with these treatments and add dermastamping.
The conversation discusses the molecular structures of compounds that reduce DHT levels, including finasteride and Ashwagandha. It explores the potential of using Ashwagandha topically as a 5a reductase inhibitor.
A 26-year-old male is considering switching from Finasteride to Dutasteride for more effective hair restoration, while others share experiences and advice on transitioning between these treatments. Many suggest gradually integrating Dutasteride with Finasteride to avoid shedding, and some report positive results with Dutasteride, though regrowth is not guaranteed.
KX826 shows promise as a hair loss treatment with a 10% increase in hair count, but concerns about Kintor's marketing practices and the systemic effects of treatments like GT20029 and RU58841 remain. Users express skepticism and hope, with some preferring traditional treatments like finasteride and minoxidil.
The user switched from topical to oral finasteride and minoxidil, noticing thicker and longer baby hairs, suggesting potential regrowth at the temples. Other users agree it looks like a sign of success.
The user noticed hair regrowth after 4 years of hair loss, coinciding with lifestyle improvements like quitting smoking, exercising, and a better diet. They are curious if dormant follicles can recover under improved conditions.
Significant hair regrowth was achieved using 1 mg Finasteride, 5% Minoxidil, and dermarolling, with a switch from a 0.5 mm to a 1 mm roller after two months. The user is happy with the results but is still considering a hair transplant for more density.
New product Tomorrowlabs HSF targets hair loss through HIF pathway indirectly by removing scalp iron. Minoxidil and Stemoxydine also relate to HIF pathway.
Significant hair regrowth was achieved using EssenGen 6-Plus with 6% minoxidil and 0.05% finasteride, along with Nizoral shampoo, over 12 weeks. No side effects were experienced, highlighting the benefits of a low dose.
The post and conversation are about a user experiencing hair regrowth after using Minoxidil 5% twice daily, topical finasteride 0.05% once daily, weekly microneedling, and ketoconazole shampoo. Other users noted visible progress and shared their own treatment experiences.
PP405 is a potential new hair loss treatment that works through metabolic pathways rather than hormonal ones, with an estimated market release between late 2027 and 2029. Current alternatives to finasteride include minoxidil, pyralutamide, fluridil, and RU58841, with hair transplants also being a viable option.
A user's journey with hair loss, starting with finasteride at age 17 and switching to dutasteride at 18. The post provides insight on how minoxidil helped initially but quitting it caused some regrowth that was regained when switching to dutasteride. There is also discussion about starting finasteride as young as 17 years old for those who may be worried about potential physical development issues.
The user experienced significant hair loss due to health issues and is now using finasteride and minoxidil for nearly 3 months. They are hopeful about tiny hairs/dots indicating regrowth and are considering a hair transplant later in the year.
The conversation discusses the potential market release of a hair loss treatment called GT20029 by Anageninc, with users expressing interest and discussing the importance of safety and effectiveness. Some users plan to contact Anageninc to show demand for the product.
The user successfully regrew thick hair using minoxidil, finasteride, and biotin, starting at age 19, and expresses gratitude to the community for support. They experienced minimal side effects and emphasize the importance of personal research and a healthy lifestyle.
PP405 is a promising new hair loss treatment that may reactivate dormant hair follicles without side effects. It could surpass traditional treatments like minoxidil and finasteride if successful in further trials.
The user is discussing hair regrowth after 3.5 months of using finasteride, questioning if the new growth is baby hairs. They compare photos from December to the present to assess progress.
An 18-year-old shared his 3-month hair regrowth progress using Kirkland 5% topical minoxidil and a dermaroller, achieving a better hairline without finasteride. He plans to switch from liquid to foam minoxidil for easier styling and is cautious about starting finasteride due to potential hormonal effects.
The user shared their journey from hair loss at 17 to a full head of hair using topical finasteride, Saw Palmetto, a natural serum with stem cells and rosemary oil, dermarolling, and a specialized shampoo. They experienced side effects with Dutasteride and found success with their current routine without side effects.
HMI-115, a newly discovered hair loss treatment that could potentially be effective for those with diffuse thinning and telogen effluvium. It is based on prolactin receptor antagonist signaling and has already undergone Phase I trials in women, with potential commercialization by 2027.
PP405 is the most promising future treatment for hair loss, aiming to reactivate dormant hair follicles. Clascoterone 5% is the most promising near-term drug, while current strategies include using finasteride or dutasteride to stabilize hair loss and minoxidil to stimulate growth.
A user trying to avoid an expensive hair transplant, and the replies suggesting they wait two years on treatment before deciding if they need a transplant or not.
Experimenting with trestolone as a treatment for hair loss in an attempt to avoid DHT-related treatments such as finasteride and dutasteride, and discussing the potential effects of its receptor selectivity on the androgen receptors in the scalp.
A user shared their hair regrowth journey from age 21 to 25 using finasteride and a carnivore diet. Other users debated the effectiveness of diet changes versus genetic factors in hair loss.
Yunce Medical, a Chinese company, is developing hair multiplication technology similar to Stemson Therapeutics, with potential for quicker availability due to favorable regulations. Users express skepticism and hope for future advancements in hair loss treatments.
PP405 is considered a promising hair loss treatment, potentially replacing minoxidil but not finasteride. Users are hopeful for future treatments like GT20029 and VDPHL01, while remaining cautious about effectiveness and side effects.